Richard Pazdur, longtime FDA oncology leader, to head agency’s main drug office

Dr. Pazdur's appointment as head of CDER brings stability to the FDA's main drug evaluation office amid staff losses and a turbulent period. This move is crucial for biotech/pharma professionals as consistent leadership can impact regulatory processes, drug approvals, and industry interactions, potentially influencing drug development timelines and market strategies.